Articles by Nichole Tucker
The phase 3 SURPASS-ET trial presented at ASCO evaluated ropeginterferon alfa-2b versus anagrelide for the treatment of ET.
Cilta-cel improves PFS and OS in len-refractory MM across subgroups, including high-risk cytogenetics, per CARTITUDE-4.
IME shows strong efficacy in LR-MDS, offering transfusion independence in heavily pretreated, ESA-ineligible patients.
EPCOR shows durable remission and survival at 2 years in R/R LBCL, with promising safety from fixed-duration treatment.
Axi-cel shows durable response in high-risk LBCL frontline treatment with 80% progression-free at 3 years in ZUMA-12 trial.
Sankalp Arora, MBBS, a second-year fellow at MD Anderson, presented data on FLT3 inhibitors in AML at the HemOnc Pulse Live.
Julie Braish, MBBCh, a third-year fellow at MD Anderson, presented data on azacitidine and venetoclax in HR-MDS and CMML.
CLL treatment is evolving. Dr. Ryan Jacobs shares why decisions now weigh indefinite therapy vs. time-defined options.
During The HemOnc Pulse Live! Nick Short, MD gave a presentation on unanswered questions in ALL.
Phase 1b data suggest that continuous low-dose lenalidomide improves the therapeutic index in patients RRMM.
Linperlisib will be investigated in a global registration study versus physician’s choice of standard treatment for R/R ...
Pallawi Torka, MD, discusses current guidelines and evidence-based strategies for managing DLBCL in older adults.
United States District Judge Sean D. Jordan entered the final judgment to vacate a new FDA regulation regarding lab tests.
Joseph G. Jurcic, MD on the journey to survivorship for adults with either AML or ALL.
Machine learning may aid point-of-care clinical decision-making for NHL patients receiving CAR T-cell therapy.
According to John O. Mascarenhas, MD, the phase 3 MANIFEST study heralds a new era of combination therapy for myelofibrosis.
Readmission rates were higher among patients with AML with high incomes compared with patients with low incomes.
BCMA–directed CAR Ts were a vital advancement to RRMM treatment. Now, oncologists wonder which agent works best.
Do IMID-containing quadruplet therapies represent both the present and future of myeloma treatment?
A retrospective study supported the safety of teclistamab and demonstrated a PFS benefit for patients with advanced myeloma.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.